Standout Papers

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons 2022 2026 2023 2024270
  1. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons (2022)
    Adel Naimi, Rebar N. Mohammed et al. Cell Communication and Signaling

Immediate Impact

32 standout
Sub-graph 1 of 16

Citing Papers

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
2024 Standout

Works of Ali Adili being referenced

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
2022 Standout
CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool
2022

Author Peers

Author Last Decade Papers Cites
Ali Adili 191 94 237 151 28 512
Yan Qu 240 113 153 119 33 492
Neşe Ünver 177 75 231 239 18 542
Fengjuan Lin 270 161 164 104 30 557
Xia Li 200 130 212 136 35 571
Ryo Sato 272 103 281 63 22 542
Aitor Benedicto 200 85 180 113 26 558
Praveen Neeli 276 72 116 123 23 487
Matteo Gallazzi 174 105 171 266 28 576
Antao Xu 219 67 240 205 20 624
Lijuan Huang 216 84 164 184 26 605

All Works

Loading papers...

Rankless by CCL
2026